Zevra Therapeutics to Report Second Quarter 2024 Financial Results
30 juil. 2024 08h38 HE
|
Zevra Therapeutics
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
09 juil. 2024 09h00 HE
|
Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
Zevra Therapeutics Expands Executive Leadership Team
25 juin 2024 07h30 HE
|
Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
03 juin 2024 11h00 HE
|
Zevra Therapeutics
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on...
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
05 oct. 2023 07h30 HE
|
Zevra Therapeutics
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra...
ORPH FINAL DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
05 sept. 2021 13h15 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
ORPH BREAKING ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ORPH
24 août 2021 17h45 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
24 juin 2020 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 36/2020 ...
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
22 mai 2020 01h52 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
03 janv. 2020 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....